Q-omics provides the consensus-scored ZNF542P profile across patient tissues and cancer cell-line models. ZNF542P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF542P is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZNF542P RNA expression shows 19,038 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ZNF542P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF542P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF542P survival associations across molecular data types. ZNF542P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF542P RNA expression–survival associations across cancer types. High ZNF542P expression shows unfavorable associations in LGG, LUSC and CHOL, but favorable associations in KIRC, UVM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF542P RNA expression.
This table summarizes ZNF542P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF542P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF542P shows lower tumor expression in KIRC, HNSC, COAD, THCA, KICH and KIRP. The KIRC box plot shows higher ZNF542P RNA expression in normal versus tumor tissue (log2 FC = −1.105, t-test p < 0.001).
This table shows molecular features associated with ZNF542P in patient tissues and cancer cell lines. In patient samples, ZNF542P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF542P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
